Meanwhile, the debate over whether CAR-T is worth the price persists. The most recent analysis, published in Health Affairs, suggested Novartis could price Kymriah at $160,000 and still make a decent profit margin. Cost watchdog ICER, on the other hand, came out on the side of Novartis and Gilead, concluding that the prices of both products make sense in light of "clinical benefits over a lifetime time horizon." Editor's note: This story has been updated to reflect different pricing for Kymriah in the lymphoma indication.